Sai Praneeth R Bathena
Overview
Explore the profile of Sai Praneeth R Bathena including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
13
Citations
197
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Callisto S, Illamola S, Birnbaum A, Barkley C, Bathena S, Leppik I, et al.
J Clin Pharmacol
. 2020 Apr;
60(9):1166-1176.
PMID: 32297992
Drug side effects that impair cognition can lead to diminished quality of life and discontinuation of therapy. Topiramate is an antiepileptic drug that elicits cognitive deficits more frequently than other...
2.
Ahn J, Bathena S, Brundage R, Conway J, Leppik I, Birnbaum A
Epilepsy Res
. 2018 Oct;
147:115-118.
PMID: 30327119
Methods: CBZ concentration data collected from 60 nursing homes across the US were evaluated. Inclusion criteria included residency in a nursing home for at least 2 months, age 65 years...
3.
Bathena S, Leppik I, Kanner A, Birnbaum A
Epilepsy Behav
. 2017 Mar;
69:116-120.
PMID: 28242474
Objective: The incidence of epilepsy is highest in the elderly and the prevalence of epilepsy is higher in nursing home residents than in other cohorts. Co-medications that act in the...
4.
Ahmed G, Bathena S, Brundage R, Leppik I, Conway J, Schwartz J, et al.
AAPS J
. 2017 Jan;
19(2):551-556.
PMID: 28070716
Pharmacokinetic data of gabapentin (GBP) in community-dwelling elderly patients show a significant effect of advanced age on GBP pharmacokinetics due to altered renal function. However, there are no data in...
5.
Bathena S, Thakare R, Gautam N, Mukherjee S, Olivera M, Meza J, et al.
Toxicol Sci
. 2014 Oct;
143(2):308-18.
PMID: 25344563
Hepatobiliary diseases result in the accumulation of bile acids (BAs) in the liver, systemic blood, and other tissues leading to an unfavorable prognosis. The BA profile was characterized by the...
6.
Bathena S, Thakare R, Gautam N, Mukherjee S, Olivera M, Meza J, et al.
Toxicol Sci
. 2014 Oct;
143(2):296-307.
PMID: 25344562
The role of bile acids (BAs) as biomarkers for liver injury has been proposed for decades. However, the large inter- and intra-individual variability of the BA profile has prevented its...
7.
Wakaskar R, Bathena S, Tallapaka S, Ambardekar V, Gautam N, Thakare R, et al.
Pharm Res
. 2014 Sep;
32(3):1028-44.
PMID: 25223962
Purpose: Determine the feasibility and potential benefit of peripherally cross-linking the shell of core-shell polymer micelles on the premature release of physically loaded hydrophobic drug in whole blood and subsequent...
8.
Bathena S, Mukherjee S, Olivera M, Alnouti Y
J Chromatogr B Analyt Technol Biomed Life Sci
. 2013 Nov;
942-943:53-62.
PMID: 24212143
The role of sulfation in ameliorating the hepatotoxicity of bile acids (BAs) in humans remains unknown due to the lack of proper analytical methods to quantify individual BAs and their...
9.
Epstein A, Narayanasamy P, Dash P, High R, Bathena S, Gorantla S, et al.
J Neuroimmune Pharmacol
. 2013 May;
8(5):1224-38.
PMID: 23702663
Metabolites are biomarkers for a broad range of central nervous system disorders serving as molecular drivers and byproducts of disease pathobiology. However, despite their importance, routine measures of brain tissue...
10.
Gautam N, Bathena S, Chen Q, Natarajan A, Alnouti Y
Biomed Chromatogr
. 2013 Mar;
27(7):900-9.
PMID: 23483555
13-197 is a novel NF-κB inhibitor that shows promising in vitro efficacy data against pancreatic cancer. In this study, we characterized the pharmacokinetics, tissue distribution, protein binding and metabolism of...